Email Alert RSS
Volume 10 Issue 5
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Yan-na ZHANG, Yi-dong ZHOU, Feng MAO, Ru YAO, Qiang SUN. Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 539-545. DOI: 10.3969/j.issn.1674-9081.2019.05.019
Citation: Yan-na ZHANG, Yi-dong ZHOU, Feng MAO, Ru YAO, Qiang SUN. Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 539-545. DOI: 10.3969/j.issn.1674-9081.2019.05.019
shu

Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    SUN Qiang Tel: 86-10-69158703, E-mail:sunqiangpumc@sina.com

  • Received Date: January 15, 2018
  • Issue Publish Date: September 29, 2019
    Graphical Abstract
    • Abstract
  •   Objective  To evaluate the prognostic value of the combination of progesterone receptor (PR) and Ki-67 index in grade 2 breast cancer with positive hormone receptor (HR) and negative axillary lymph node.
      Methods  The clinical and pathological data of patients with grade 2 breast cancer who underwent surgical treatment and 21 genes' recurrence score (RS) testing in the department of Breast Surgery, Peking Union Medical College Hospital from May 2012 to May 2017 were retrospectively analyzed. According to the 21 genes' RS, patients were divided into RS low-risk group (RS < 18), RS intermediate-risk group (18≤RS < 31), and RS high-risk group (RS≥31). At the same time, the combination of PR and Ki-67 index (PK) was set according to the expression of PR and Ki-67 index. The patients were divided into PK low-risk group (PR≥10% and Ki-67≤20%), PK high-risk group (PR < 10% and Ki-67>20%), and PK intermediate-risk group (non-high or low-risk group). The consistency of the PK combination and 21 genes' RS was analyzed and compared.
      Results  A total of 389 patients who met the inclusive and exclusive criteria were enrolled in this study, including 247 patients in RS low-risk group (63.5%, 247/389), 115 in RS intermediate risk group (29.6%, 115/389), 27 in RS high-risk group (6.9%, 27/389), 248 in PK low-risk group (63.8%, 248/389), 125 in PK intermediate risk group (32.1%, 125/389), 16 in PK high-risk group (4.1%, 16/389). The predictive sensitivity of the recommended PK combination for RS low risk and high-risk group was 75.3% and 37.0%, respectively, with the positive predictive values of 75.0% and 62.5%, and the inconsistency of 0.4% and 6.3%, respectively. After a median follow-up of 40 months, the total incidence of locoregional recurrence (LRR) and distant metastasis (DM) in PK low, intermediate, and high-risk group was 3.6%, 7.2%, and 12.5%, respectively. The total incidence of LRR and DM in RS low, intermediate, and high-risk groups was 3.2%, 8.7%, and 7.4%, respectively. There was no significant difference between PK combination and RS (P=0.655).
      Conclusion  The prognostic value of PK combination for HR-positive grade 2 early-stage breast cancer with negative axillary lymph nodes is comparable to that of the 21 genes' RS.
    • FullText(HTML)
    • References (21)
  • [1]
    Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14:324-354. DOI: 10.6004/jnccn.2016.0037
    [2]
    Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer:results from NSABP B-14 and NSABP B-20[J]. J Clin Oncol, 2010, 28:1677-1683. DOI: 10.1200/JCO.2009.23.7610
    [3]
    Zhang YN, Zhou YD, Mao F, et al. Impact of the 21-Gene Recurrence Score Assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population[J]. Neoplasma, 2015, 62:658-665. DOI: 10.4149/neo_2015_079
    [4]
    Toi M, Iwata H, Yamanaka T, et al. Clinical significance of the 21-gene signature(Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population[J]. Cancer, 2010, 116:3112-3118. DOI: 10.1002/cncr.25206
    [5]
    Lee MH, Han W, Lee JE, et al. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea[J]. Cancer Res Treat, 2015, 47:208-214. http://europepmc.org/articles/PMC4398124/
    [6]
    Henry NL, Braun TM, Ali HY, et al. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry[J]. Cancer, 2017, 123:948-956. DOI: 10.1002/cncr.30429
    [7]
    Zeng Y, Li Q, Qin T, et al. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer:A Prospective Study[J]. Anticancer Res, 2017, 37:4539-4547. http://www.ncbi.nlm.nih.gov/pubmed/28739750
    [8]
    张燕娜, 周易冬, 茅枫, 等. 21基因检测复发风险评分在激素受体阳性早期乳腺癌临床治疗和预后评估中的价值[J].中华肿瘤杂志, 2018, 2:110-114. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhzl201802006
    [9]
    Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer:estrogen receptor positive progesterone receptor negative[J]. Oncologist, 2011, 16:276-285. DOI: 10.1634/theoncologist.2010-0302
    [10]
    Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J]. J Clin Oncol, 2013, 31:203-209. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5411e2931d23233da9ce5fe94600509c
    [11]
    Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24:2206-2223. DOI: 10.1093/annonc/mdt303
    [12]
    Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index[J]. BMC Cancer, 2017, 17:354-362. DOI: 10.1186/s12885-017-3331-4
    [13]
    Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133:1710-1715. http://www.tandfonline.com/servlet/linkout?suffix=cit0008&dbid=8&doi=10.1080%2F2162402X.2015.1066062&key=6206131
    [14]
    Nishimura R, Osako T, Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis[J]. Breast Cancer, 2010, 17:269-275. DOI: 10.1007/s12282-009-0161-5
    [15]
    Honma N, Horii R, Iwase T, et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy[J]. Breast Cancer, 2015, 22:71-78. DOI: 10.1007/s12282-013-0455-5
    [16]
    Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer:the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28:1700-1712. DOI: 10.1093/annonc/mdx308
    [17]
    Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast and Gynecopathologists[J]. PLoS One, 2012, 7:e37379. DOI: 10.1371/journal.pone.0037379
    [18]
    Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopa-thologic variables predict Oncotype DX recurrence score[J]. Mod Pathol, 2008, 21:1255-1261. http://www.nature.com/modpathol/journal/v21/n10/abs/modpathol200854a.html
    [19]
    Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29:4273-4278. DOI: 10.1200/JCO.2010.31.2835
    [20]
    Geradts J, Bean SM, Bentley RC, et al. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features[J]. Cancer Invest, 2010, 28:969-977. DOI: 10.3109/07357907.2010.512600
    [21]
    Turner BM, Skinner KA, Tang P, et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score[J]. Mod Pathol, 2015, 28:921-931. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=fb2bfaca0f340dad9a678b4060cee5e8
    • Related Articles

  • Related Articles

    [1]YAO Ru, YANG Xu, QU Yang, LIAN Jie, ZHANG Jiahui, HUANG Xin, CHEN Chang, REN Xinyu, PAN Bo, ZHOU Yidong, SUN Qiang. PTEN Mutation Related Unilateral Multicentric, Synchronous and Metachronous Bilateral Breast Cancer: Three Case Reports[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 916-920. DOI: 10.12290/xhyxzz.2023-0550
    [2]QU Yang, ZHANG Yanna, ZHOU Yidong, SUN Qiang. Application of 21-gene Recurrence Score in Hormone Receptor Positive Breast Cancer Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1274-1281. DOI: 10.12290/xhyxzz.2023-0226
    [3]QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023
    [4]XIONG Xuechun, WU Huanwen, REN Fei, CUI Li, LIANG Zhiyong, ZHAO Ze. An Automatic Quantitative Analysis Method of Ki-67 Index for Breast Cancer Immunohistochemistry Based on Fusion of Spatial and Multi-scale Features[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 581-589. DOI: 10.12290/xhyxzz.2022-0158
    [5]CHEN Wen, ZHOU Zhou. Application of Genetic Testing in Precision Medicine for Coronary Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 445-449. DOI: 10.12290/xhyxzz.2021-0418
    [6]Qi JIN, Qin LUO, Zhi-hui ZHAO, Zhi-hong LIU. MicroRNA-21 in the Pathogenesis of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 430-438. DOI: 10.3969/j.issn.1674-9081.2020.04.013
    [7]MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006
    [8]Xiao-hua SHI, Zhi-yong LIANG, Huan-wen WU, Xin-yu REN, Tong-hua LIU. Effect of RNA Interference Plasmid on the Expression of Oncogene AKT2 in Pancreatic Cancer Cell Line Panc-1[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 102-108. DOI: 10.3969/j.issn.1674-9081.2012.01.021
    [9]Xin-yu REN, Yu-feng YIN, Jie GAO, Sha-fei WU, Ke WANG, Wen-ze WANG, Xuan ZENG, Zhi-yong LIANG. Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 21-25. DOI: 10.3969/j.issn.1674-9081.2012.01.006
    [10]Jing YANG, Bao-lai HUA, Shu-jie WANG, Chang-wen GE, Lian-kai FAN, Ye-hua HAN, Yong-qiang ZHAO. Fechtner Syndrome in a Chinese Family: A Case Report and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 171-175.

  • Cited by

    Periodical cited type(16)

    1. 刘晓明，武宜雷，刘学键. 示踪剂盐酸米托蒽醌在甲状腺癌根治术中的应用. 局解手术学杂志. 2024(01): 66-68 .
    2. 郎罡，李馨颐，王淑君. 新型淋巴示踪剂—示踪用盐酸米托蒽醌注射液. 中国临床药理学杂志. 2024(04): 615-618 .
    3. 张为良，周鹏，李小磊，朱见，庄大勇，岳涛，徐婧，贺青卿. 示踪剂米托蒽醌和纳米炭在机器人甲状腺癌手术中的应用效果比较. 中国普通外科杂志. 2024(05): 762-771 .
    4. 陶星儒，石臣磊，石铁锋，吴罡，刘英明，董加宇. 示踪用盐酸米托蒽醌在甲状腺乳头状癌术中应用研究. 中国实用外科杂志. 2024(06): 685-691 .
    5. 盛浩，白俊文，王霞. 甲状旁腺显影技术在甲状腺手术中的应用研究进展. 癌症进展. 2024(10): 1057-1061 .
    6. 麻紫月，张翊伦. 慢性肾衰继发甲状旁腺功能亢进的手术治疗. 中国临床研究. 2024(06): 946-949 .
    7. 宁小晶，汪洪宇，傅丽元，殷毅，花苏榕. 示踪用盐酸米托蒽醌注射液在经胸前入路腔镜甲状腺癌手术中的应用价值. 中华内分泌外科杂志. 2024(03): 377-382 .
    8. 胡振涛，吴延花，花亚军，李明. 示踪剂联合长型Trocar在腔镜甲状腺癌根治术中的应用效果分析. 中国社区医师. 2024(16): 59-61 .
    9. 余亮，陈先恒，李海涛. 自体荧光联合示踪用盐酸米托蒽醌注射液在甲状腺术中识别甲状旁腺的临床应用. 中国现代普通外科进展. 2024(07): 549-553 .
    10. 程宇，张爽，刘智伟，刘莉莉，王毅，顾建华. 新型示踪剂盐酸米托蒽醌在甲状腺癌根治术中淋巴结显影的应用探究. 中华耳鼻咽喉头颈外科杂志. 2024(10): 1064-1071 .
    11. 杨犇龙，焦得闯，陈嘉健，王春建，金利丹，赵文和，高学强，王海波，李珺，赵海东，吴迪，范志明，王淑君，刘真真，王永胜，吴炅. 示踪用盐酸米托蒽醌注射液与核素用于乳腺癌前哨淋巴结活检的疗效对比研究. 中国癌症杂志. 2023(02): 126-133 .
    12. 徐磊，周鹏，庄大勇，李小磊，岳涛，贺青卿. 甲状旁腺自体荧光联合纳米碳在甲状腺癌术中应用. 中华内分泌外科杂志. 2023(01): 19-23 .
    13. 刘凯，刘伟，刘昊中，李云龙，唐立. 老年甲状腺开放手术患者喉返神经损伤的相关因素及其预防. 中国老年学杂志. 2023(19): 4717-4721 .
    14. 顾建华，程宇，于娟，魏晓宇，叶伟，高宇，孙桂森，王毅. 示踪用盐酸米托蒽醌注射液对甲状腺癌前哨淋巴结示踪疗效及对甲状旁腺功能的保护作用研究. 中国临床药理学杂志. 2022(20): 2392-2395 .
    15. 中国医疗保健国际交流促进会甲状腺疾病防治分会，中华预防医学会甲状腺疾病防治专业委员会，中国人体健康科技促进会甲状腺肿瘤专业委员会. 甲状腺癌手术中淋巴结示踪技术规范应用专家共识. 中华医学杂志. 2022(48): 3836-3841 .
    16. 彭钰蓓，叶梦醒，马可欣，寇震，刘丽萍. 甲状旁腺功能亢进症术前和术中定位病变甲状旁腺的研究进展. 中国普通外科杂志. 2022(11): 1518-1526 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (464) PDF downloads (94) Cited by(20)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close